Back to Search

ANITA HANCOCK, MD

MD

Pediatrics Physician

NPI: 1487634408Individual

Specialties, Licenses & Credentials

Pediatrics PhysicianPrimary

Pediatrics

Code: 208000000X

R3N75(MO)MD211746(OR)

Research & Publications (20)

Public speaking attitudes: does curriculum make a difference?
PMID 19481418·J Voice·2010
8-other
Does 5-bromo-2'-deoxyuridine (BrdU) disrupt cell proliferation and neuronal maturation in the adult rat hippocampus in vivo?
PMID 19121338·Behav Brain Res·2009
7-preclinical
The challenge of drug discovery of a GPCR target: analysis of preclinical pharmacology of histamine H3 antagonists/inverse agonists.
PMID 16513092·Biochem Pharmacol·2006
6-review
Distinctions and contradistinctions between antiobesity histamine H(3) receptor (H (3)R) antagonists compared to cognition-enhancing H (3) receptor antagonists.
PMID 16547814·Inflamm Res·2006
7-preclinical
Assessment of pharmacology and potential anti-obesity properties of H3 receptor antagonists/inverse agonists.
PMID 15833055·Expert Opin Investig Drugs·2005
6-review
Antiobesity evaluation of histamine H3 receptor (H3R) antagonist analogs of A-331440 with improved safety and efficacy.
PMID 15928821·Inflamm Res·2005
7-preclinical
In vitro optimization of structure activity relationships of analogues of A-331440 combining radioligand receptor binding assays and micronucleus assays of potential antiobesity histamine H3 receptor antagonists.
PMID 15447739·Basic Clin Pharmacol Toxicol·2004
7-preclinical
Perspectives on cognitive domains, H3 receptor ligands and neurological disease.
PMID 15461554·Expert Opin Investig Drugs·2004
6-review
Histamine H(3) antagonists in models of obesity.
PMID 15054613·Inflamm Res·2004
7-preclinical
Antiobesity effects of A-331440, a novel non-imidazole histamine H3 receptor antagonist.
PMID 15033391·Eur J Pharmacol·2004
7-preclinical
H3 receptor antagonists/inverse agonists as anti-obesity agents.
PMID 14649210·Curr Opin Investig Drugs·2003
6-review
Microparticle column geometry in acoustic stationary fields.
PMID 12558301·J Acoust Soc Am·2003
8-other
Genetic and pharmacological aspects of histamine H3 receptor heterogeneity.
PMID 14550847·Life Sci·2003
6-review
Preclinical pharmacology of fiduxosin, a novel alpha(1)-adrenoceptor antagonist with uroselective properties.
PMID 11805207·J Pharmacol Exp Ther·2002
7-preclinical
Circulating monocytes in HIV-1-infected viremic subjects exhibit an antiapoptosis gene signature and virus- and host-mediated apoptosis resistance.
PMID 19299747·J Immunol·2009
8-other
Kinematic gait adaptations in unilateral transtibial amputees during rehabilitation.
PMID 19367517·Prosthet Orthot Int·2009
4-observational
Design of a new histamine H3 receptor antagonist chemotype: (3aR,6aR)-5-alkyl-1-aryl-octahydropyrrolo[3,4-b]pyrroles, synthesis, and structure-activity relationships.
PMID 19588934·J Med Chem·2009
7-preclinical
Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
PMID 18811133·J Med Chem·2008
7-preclinical
The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
PMID 18683917·J Med Chem·2008
7-preclinical
Increased soluble vascular cell adhesion molecule-1 plasma levels and soluble intercellular adhesion molecule-1 during antiretroviral therapy interruption and retention of elevated soluble vascular cellular adhesion molecule-1 levels following resumption of antiretroviral therapy.
PMID 18525261·AIDS·2008
2-rct

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Address
610 NW 11TH ST STE E33
HERMISTON, OR 97838

Location

Practice Location

610 NW 11TH ST STE E33, HERMISTON, OR
(541) 667-3740

Quick Facts

NPI
1487634408
Entity Type
Individual
Gender
Female
Medicare
Not confirmed
Specialties
2
Locations
1
Publications
20

Are you this provider?

Claim Your Profile